Ascendis Pharma A/S (NASDAQ:ASND) Earns Overweight Rating from Analysts at Morgan Stanley

Equities research analysts at Morgan Stanley began coverage on shares of Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) in a report issued on Thursday. The firm set an "overweight" rating and a $250.00 price target on the biotechnology company's stock. Morgan Stanley's price target indicates a potential upside of 44.43% from the stock's previous close.

ASND has been the subject of several other research reports. Evercore ISI lifted their price target on Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. JPMorgan Chase & Co. raised their price objective on Ascendis Pharma A/S from $200.00 to $245.00 and gave the company an "overweight" rating in a research note on Friday, May 2nd. Bank of America boosted their target price on Ascendis Pharma A/S from $201.00 to $216.00 and gave the company a "buy" rating in a research report on Monday, June 9th. Wedbush increased their price target on Ascendis Pharma A/S from $181.00 to $212.00 and gave the company an "outperform" rating in a report on Friday, May 2nd. Finally, Royal Bank Of Canada raised their price target on Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. One investment analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $220.67.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $173.10 on Thursday. The stock has a market capitalization of $10.58 billion, a PE ratio of -27.56 and a beta of 0.38. The company's fifty day moving average is $167.21 and its 200 day moving average is $151.65. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing analysts' consensus estimates of ($1.56) by ($0.10). The business had revenue of $123.97 million for the quarter, compared to analyst estimates of $98.56 million. As a group, research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Institutional Trading of Ascendis Pharma A/S

Institutional investors and hedge funds have recently made changes to their positions in the business. Virtus ETF Advisers LLC increased its stake in Ascendis Pharma A/S by 3.9% in the 4th quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock worth $368,000 after buying an additional 100 shares during the period. PNC Financial Services Group Inc. grew its stake in Ascendis Pharma A/S by 2.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 8,578 shares of the biotechnology company's stock worth $1,337,000 after acquiring an additional 195 shares in the last quarter. Jones Financial Companies Lllp grew its stake in Ascendis Pharma A/S by 394.0% in the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Ascendis Pharma A/S during the fourth quarter worth approximately $28,000. Finally, Brooklyn Investment Group increased its position in shares of Ascendis Pharma A/S by 332.9% during the first quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company's stock worth $55,000 after acquiring an additional 273 shares during the period.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.